Pulmonx Corporation (LUNG) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -103.52%, forward earnings yield 102.04%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -44.1 | 0.00 | -4.87 | 40.70 | - |
| 2019 | -67.3 | 1.93 | -7.43 | 42.72 | - |
| 2020 | -76.4 | -1.39 | 10.89 | 75.26 | - |
| 2021 | -23.8 | -0.48 | 6.00 | 23.93 | - |
| 2022 | -5.3 | -0.30 | 2.03 | 5.83 | - |
| 2023 | -8.0 | -12.65 | 4.09 | 7.05 | - |
| 2024 | -4.7 | 0.47 | 3.09 | 3.17 | - |
| 2025 | -1.7 | 0.22 | 1.66 | 0.99 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.89 | $20M | $-18.48M | -92.4% |
| 2019 | $-0.58 | $32.6M | $-20.7M | -63.5% |
| 2020 | $-0.90 | $32.73M | $-32.23M | -98.5% |
| 2021 | $-1.35 | $48.42M | $-48.66M | -100.5% |
| 2022 | $-1.59 | $53.66M | $-58.92M | -109.8% |
| 2023 | $-1.60 | $68.68M | $-60.84M | -88.6% |
| 2024 | $-1.44 | $83.79M | $-56.39M | -67.3% |
| 2025 | $-1.33 | $90.5M | $-54M | -59.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.10 | $-1.13 – $-1.07 | $90.87M | $90.71M – $91.03M | 4 |
| 2027 | $-0.86 | $-0.92 – $-0.78 | $107.71M | $104.71M – $110.7M | 4 |
| 2028 | $-0.19 | $-3.48 – $3.09 | $155.13M | $148.34M – $173.84M | 2 |
| 2029 | $1.54 | $1.45 – $1.78 | $271.17M | $259.3M – $303.87M | 1 |
| 2030 | $2.80 | $2.64 – $3.24 | $364.71M | $348.75M – $408.69M | 1 |
